Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

With Questions Surrounding Its Gastric Cancer Drug, Amgen Fills in some Gaps

Summary by STAT
Revised analysis of data on the drug, called bemarituzumab, had led to uncertainty about benefits, amid questions about possible safety issues as well.

2 Articles

STATSTAT
Center

With questions surrounding its gastric cancer drug, Amgen fills in some gaps

Revised analysis of data on the drug, called bemarituzumab, had led to uncertainty about benefits, amid questions about possible safety issues as well.

·Boston, United States
Read Full Article
endpoints.newsendpoints.news

Amgen, Zai Lab detail reduced survival benefit in stomach cancer trial

Amgen & Zai Lab reveal survival benefit decline for stomach cancer drug bemarituzumab in Phase 3 trial, with median survival dropping from 17.9 to 14.5 months at longer follow-up

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Sunday, October 19, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Amgen icon

Amgen

Germany icon

Germany

News
For You
SearchBlindspotLocal